Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia

References

• CameronEEBaylinSBHermanJGp15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencingBlood19999472445245110498617
   PubMed Web of Science ®Google Scholar
• KroegerHJelinekJEstécioMRHAberrant CpG island methylation in acute myeloid leukemia is accentuated at relapseBlood200811241366137318523155
   PubMed Web of Science ®Google Scholar
• FigueroaMELugthartSLiYDNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemiaCancer Cell2010171132720060365
   PubMed Web of Science ®Google Scholar
• SaiedMHMarzecJKhalidSGenome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeatsPLoS One201273e3321322479372
   PubMed Web of Science ®Google Scholar
• KnippSHildebrandBKündgenAIntensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypesCancer2007110234535217559141
   PubMed Web of Science ®Google Scholar
• JuliussonGAntunovicPDerolfÅAge and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood2009113184179418719008455
   PubMed Web of Science ®Google Scholar
• GrimwadeDWalkerHHarrisonGThe predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood20019851312132011520776
   PubMed Web of Science ®Google Scholar
• StoneRMThe difficult problem of acute myeloid leukemia in the older adultCA Cancer J Clin200252636337112469764
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSCortesJResults of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndromeCancer200610651090109816435386
   PubMed Web of Science ®Google Scholar
• EleniLDNicholasZCAlexandrosSChallenges in treating older patients with acute myeloid leukemiaJ Oncol2010201094382320628485
   PubMedGoogle Scholar
• Van Der HoltBBreemsDABerna BeverlooHVarious distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trialBr J Haematol200713619610517129222
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
   PubMed Web of Science ®Google Scholar
• DeschlerBWitteT deMertelsmannRLuebbertMTreatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approachesHaematologica200691111513152217082009
   PubMed Web of Science ®Google Scholar
• BurnettAKMilliganDPrenticeAGA comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer200710961114112417315155
   PubMed Web of Science ®Google Scholar
• KantarjianHMThomasXGDmoszynskaAMulticenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaJ Clin Oncol201230212670267722689805
   PubMed Web of Science ®Google Scholar
• SchaeferMHagemannSHannaKLykoFAzacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell linesCancer Res200969208127813219808971
   PubMed Web of Science ®Google Scholar
• ChristmanJK5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene200221355483549512154409
   PubMed Web of Science ®Google Scholar
• HollenbachPWNguyenANBradyHA comparison of azacitidine and decitabine activities in acute myeloid leukemia cell linesPLoS One201052e900120126405
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstroem-LindbergEAzacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaJ Clin Oncol201028456256920026804
   PubMed Web of Science ®Google Scholar
• Al-AliHKJaekelNJunghanssCAzacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II studyLeuk Lymphoma201253111011721767242
   PubMed Web of Science ®Google Scholar
• MaurilloLVendittiASpagnoliAAzacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate ProgramCancer201211841014102221761399
   PubMed Web of Science ®Google Scholar
• KornblithABHerndonJE2ndSilvermanLRImpact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III Trial: A Cancer and Leukemia Group B StudyJ Clin Oncol200220102441245212011121
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMKopeckyKJRevised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJ Clin Oncol200321244642464914673054
   PubMed Web of Science ®Google Scholar
• Roman-GomezJJimenez-VelascoAAgirreXPromoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemiaOncogene200524487213722316170379
   PubMed Web of Science ®Google Scholar
• Roman-GomezJCastillejoJAJimenezACadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfaJ Clin Oncol20032181472147912697869
   PubMed Web of Science ®Google Scholar
• GoreSDBaylinSSugarECombined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasmsCancer Res200666126361636916778214
   PubMed Web of Science ®Google Scholar
• RajKJohnAHoACDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidineLeukemia20072191937194417611569
   PubMed Web of Science ®Google Scholar
• FandyTEHermanJGKernsPEarly epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesBlood2009114132764277319546476
   PubMed Web of Science ®Google Scholar
• TranHTKimHNLeeIKDNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndromeJ Korean Med Sci201126220721321286011
   PubMed Web of Science ®Google Scholar
• YangASDoshiKDChoiSWDNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemiaCancer Res200666105495550316707479
   PubMed Web of Science ®Google Scholar
• YanPFrankhouserDMurphyMGenome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaBlood2012120122466247422786882
   PubMed Web of Science ®Google Scholar
• LiLHOlinEJBuskirkHHReinekeLMCytotoxicity and mode of action of 5-azacytidine on L1210 leukemiaCancer Res19703011276027695487063
   PubMed Web of Science ®Google Scholar
• AimiuwuJWangHChenPRNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaBlood2012119225229523822517893
   PubMed Web of Science ®Google Scholar
• IssaJPKantarjianHMTargeting DNA methylationClin Cancer Res200915123938394619509174
   PubMed Web of Science ®Google Scholar
• Sánchez-AbarcaLIGutierrez-CosioSSantamaríaCImmunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation settingBlood2010115110712119887673
   PubMed Web of Science ®Google Scholar
• XiaoWHodgeDRWangLYangXZhangXFarrarWLNF-kappaB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFkappaB regulatory site in autocrine human multiple myeloma cellsCancer Biol Ther20043101007101715467434
   PubMed Web of Science ®Google Scholar